MEPACT Trademark

Trademark Overview

On Friday, December 16, 2016, a trademark application was filed for MEPACT with the United States Patent and Trademark Office. The USPTO has given the MEPACT trademark a serial number of 79202391. The federal status of this trademark filing is Section 71 & 15 - ACCEPTED AND ACKNOWLEDGED as of Wednesday, April 10, 2024. This trademark is owned by TAKEDA FRANCE SAS. The MEPACT trademark is filed in the Pharmaceutical Products category with the following description:

Chemicals for preparations for medical or veterinary use, namely, muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), Nacetylmuramyl- L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2- dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, namely, liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, namely, mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations, namely, for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, namely, mucositis, myelosuppression, peripheral neuropathy
mepact

General Information

Serial Number79202391
Word MarkMEPACT
Filing DateFriday, December 16, 2016
Status739 - Section 71 & 15 - ACCEPTED AND ACKNOWLEDGED
Status DateWednesday, April 10, 2024
Registration Number5258435
Registration DateTuesday, August 8, 2017
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, May 23, 2017

Trademark Statements

Goods and ServicesChemicals for preparations for medical or veterinary use, namely, muramyl peptides and muramyl tripeptides, muramyl tripeptide phosphatidyl ethanolamine (MTP-PE), Nacetylmuramyl- L-alanyl-D-isoglutaminyl-L-alanine-2-(1,2- dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamide, hexopyranose and formulations of muramyl peptides, namely, liposomal formulations, pharmaceutically acceptable forms of muramyl peptides, pharmaceutically acceptable salts of muramyl peptides, all of these products being more specifically meant to be used for anti-cancer therapy, antiviral therapy, neoplasia and pathologies induced by chemotherapy, namely, mucositis, myelosuppression, peripheral neuropathy; pharmaceutical preparations, namely, for anti-cancer and antiviral therapies, neoplasia, and pathologies induced by chemotherapy, namely, mucositis, myelosuppression, peripheral neuropathy

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, February 28, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameTAKEDA FRANCE SAS
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressFR
Party NameTAKEDA FRANCE SAS
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressFR
Party NameTAKEDA FRANCE SAS
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressFR

Trademark Events

Event DateEvent Description
Friday, March 17, 2017ASSIGNED TO EXAMINER
Thursday, February 23, 2017SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Tuesday, February 28, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, March 4, 2017APPLICATION FILING RECEIPT MAILED
Monday, March 20, 2017NON-FINAL ACTION WRITTEN
Tuesday, March 21, 2017NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, March 22, 2017REFUSAL PROCESSED BY MPU
Wednesday, March 22, 2017NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, March 31, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, March 31, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Saturday, April 8, 2017REFUSAL PROCESSED BY IB
Monday, April 10, 2017CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, April 10, 2017TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, April 10, 2017ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, April 10, 2017TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, April 11, 2017TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, April 14, 2017APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, May 3, 2017NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, May 23, 2017PUBLISHED FOR OPPOSITION
Thursday, May 11, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Tuesday, May 23, 2017OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, August 8, 2017REGISTERED-PRINCIPAL REGISTER
Wednesday, November 8, 2017FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Friday, December 1, 2017FINAL DISPOSITION PROCESSED
Friday, December 1, 2017FINAL DISPOSITION NOTICE SENT TO IB
Friday, December 22, 2017FINAL DECISION TRANSACTION PROCESSED BY IB
Friday, June 22, 2018TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, August 29, 2019TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 1, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Wednesday, July 1, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Wednesday, July 1, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Wednesday, July 1, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Wednesday, July 1, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, July 1, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, July 2, 2020REVIEW OF CORRESPONDENCE COMPLETE - ADDRESS UPDATED
Monday, August 17, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 17, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 17, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 17, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 17, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 23, 2020NEW REPRESENTATIVE AT IB RECEIVED
Monday, August 8, 2022COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
Thursday, August 3, 2023TEAS SECTION 71 & 15 RECEIVED
Friday, September 1, 2023CHANGE OF NAME/ADDRESS REC'D FROM IB
Tuesday, April 9, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Wednesday, April 10, 2024REGISTERED - SEC. 71 ACCEPTED & SEC. 15 ACK.
Wednesday, April 10, 2024NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Friday, February 28, 2025NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

mepact muramyl namely peptides therapy neoplasia antiviral pharmaceutically cancer pathologies anti